Anti-CD20/CD3 Bispecific Antibody EX103

**Semantic type:** Amino Acid, Peptide, or Protein|Immunologic Factor|Pharmacologic Substance

**Definition:** A bispecific antibody targeting both the tumor-associated antigen (TAA) CD20 and the T-cell surface antigen CD3, with potential immunomodulating and antineoplastic activities. Upon administration, anti-CD20/CD3 bispecific antibody EX103 binds to both CD3 on T-cells and CD20 on CD20-expressing B-lineage tumor cells. The resulting cross-linkage may trigger a potent cytotoxic T-lymphocyte (CTL) response against the CD20-expressing tumor B cells. CD20 is exclusively expressed on B cells during most stages of B-cell development and is often overexpressed in B-cell malignancies.

**Synonyms:** - Anti-CD20/Anti-CD3 Bispecific Antibody EX103 - CD20 x CD3 Bispecific Antibody EX103 - CD3 x CD20 BiAb EX103 - EX 103 - EX-103 - EX103